BrainStorm Cell Therapeutics Inc (BCLI)

[midastouch017]

I do hope the treatment will be approved,
for my sake as a shareholder as well as
for all ALS patients, but one has to be
realistic and read the following:

DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.

Notwithstanding: Go NurOwn® Go!